Drug Trial Radar · NCT02476942
A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
Last checked: Nov 19, 2026Latest source record: May 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
May 26, 2015
Primary completion
Mar 31, 2017
Study completion Mar 31, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 22, 2015
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL, and safety in patients with hemophilia A with or without FVIII inhibitors treated according to local routine clinical practice (receiving FVIII replacement or bypassing agents as either episodic or prophylactic treatment). Actual patients will be enrolled from routine clinical practice in this observational study.
Conditions
- Hemophilia A
Interventions
Bypassing AgentsDrug
Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
FVIII ReplacementDrug
Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of BleedsTime frame: Approximately 6 months (from Baseline until study completion)
Locations
35 sites in 12 countries. Site status is shown where the registry gives one.
Santa Monica Oncology Center
Santa Monica, California
University of Colorado Denver, Children's Hospital
Aurora, Colorado
Georgetown Uni Medical Center; Lombardi Cancer Center
Washington D.C., District of Columbia
Winship Cancer Institute
Atlanta, Georgia
Tulane Uni Health Sciences Center
New Orleans, Louisiana
Children's Hospital of Michigan; Pediatrics
Detroit, Michigan
Cornell Univ Medical College; Hematology-Oncolog
New York, New York
Oregon Health & Science Uni ; Dept of Pediatrics
Portland, Oregon
University of Pittsburgh
Pittsburgh, Pennsylvania
Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia
Seattle, Washington
Royal Prince Alfred Hospital; Haematology
Camperdown, New South Wales, Australia
The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit
Melbourne, Victoria, Australia
Peking Union Medical College Hospital
Beijing, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, China
ICIC
San José, Costa Rica
Universitätsklinikum Bonn (AöR); Inst. für Experimentelle Hämatologie u. Transfusionsmedizin (IHT)
Bonn, Germany
IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
Milan, Lombardy, Italy
AOU Careggi; SOD Malattie Emorragiche
Florence, Tuscany, Italy
Nagoya University Hospital
Aichi, Japan
Hyogo College of Medicine Hospital
Hyōgo, Japan
St. Marianna University School of Medicine Hospital
Kanagawa, Japan
Hospital of the University of Occupational and Environmental Health,Japan
Kitakyushu-shi, Japan
Nara Medical University Hospital
Nara, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
Gdansk, Poland
SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
Lublin, Poland
ALVAMED Lekarskie Gabinety Specjalistyczne
Poznan, Poland
Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
Warsaw, Poland
Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center
Johannesburg, South Africa
Severance Hospital
Seoul, South Korea
Hospital Universitario la Paz; Servicio de Hematologia
Madrid, Spain
Hospital Universitario Virgen del Rocio; Servicio de Hematologia
Seville, Spain
Hospital Universitario la Fe; Servicio de Hematologia
Valencia, Spain
National Taiwan Uni Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.